Novartis blockbuster slate boosts partners' stock
This article was originally published in Scrip
The UK firm Vernalis saw its share price rise by 10% to 42.36 pence after Novartis included its novel heat shock protein 90 (HSP90) inhibitor AUY922 in a list of seven potential blockbusters in its pipeline, even though the first planned submission is not slated to take place until 2015 or later.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.